Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs

Journal of Clinical Psychiatry

Volumn 70, Issue 6, 2009, Pages 906-912

  Mohamed, Somaia ^a,b   Leslie, Douglas L ^c   Rosenheck, Robert A ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; COMORBIDITY; CONTROLLED STUDY; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL SERVICE; MENTAL HEALTH SERVICE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; VETERAN;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HOSPITALS, VETERANS; HUMANS; MALE; MIDDLE AGED; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VETERANS;

EID: 67649199944     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04450     Document Type: Article

References (39)

1. US Food and Drug Administration approves Abilify (aripiprazole) as the first medication for add-on treatment of major depressive disorder (MDD) [news release]. Bristol-Myers Squibb; November 20, 2007. Available at: http://newsroom.bms.com/ article-display.cfm?article-id=5222. Accessibility verified Jan 21, 2009
2. Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatmentrefractory major depressive disorder: a randomized trial. Ann Intern Med 2007;147(9):593-602 (Pubitemid 351664478)
3. World Health Organization. Revised global burden of disease (GBD) 2002 estimates. 2005. World Health Organization Web site. Available at: http://www.who.int/healthinfo/global-burden-disease/estimates-regional-2002- revised/en/index.html. Accessibility verified Feb 23, 2009
4. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289(23):3095-3105 (Pubitemid 37432885)
5. Johnson J, Horwath E, Weissman MM. The validity of major depression with psychotic features based on a community study. Arch Gen Psychiatry 1991;48(12):1075-1081
6. Ohayon MM, Schatzberg AF. Prevalence of depressive episodes with psychotic features in the general population. Am J Psychiatry 2002; 159(11):1855-1861 (Pubitemid 35283250)
7. Rothschild AJ, et al. Challenges in differentiating and diagnosing psychotic depression. Psychiatr Ann 2006;36(1):40-46 (Pubitemid 43171427)
8. Trivedi MH. Treatment-resistant depression: new therapies on the horizon. Ann Clin Psychiatry 2003;15(1):59-70 (Pubitemid 36723641)
9. O'Reardon JP, Amsterdam JD. Treatment-resistant depression: progress and limitations. Psychiatr Ann 1998;28:633-640 (Pubitemid 128160720)
10. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68(6):843-853 (Pubitemid 47015482)
11. Shekelle P, Maglione M, Bagley S, et al. Comparative effectiveness of off-label use of atypical antipsychotics. In: Comparative Effectiveness Review No. 6. Rockville, MD: Agency for Healthcare Research and Quality, US Dept of Health and Human Services. January 2007. AHRQ publication 07-EHC003-EF. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessibility verified Jan 26, 2009
12. Worthington JJ 3rd, Kinrys G, Wygant LE, et al. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005;20(1):9-11
13. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158(1):131-134 (Pubitemid 32047260)
14. Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004;65(2):217-221
15. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999; 60(4):256-259 (Pubitemid 29193925)
16. Adson DE, Kushner MG, Eiben KM, et al. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety 2004;19(2):121-126 (Pubitemid 38387604)
17. Nemeroff CB, Gharabawi GM, Canuso CM, et al. Augmentation with risperidone in chronic resistant depression: a double-blind placebo controlled maintenance trial. Neuropsychopharmacology 2004;29 (suppl 1):S159
18. Dube S, Anderson SW, Paul S. Meta-analysis of olanzapine-fluoxetine use in treatment-resistant depression. Int J Neuropsychopharmacol 2002;5(suppl 1):105-106
19. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004;30(2):193-217
20. Frasure-Smith N, Lesperance F. Reflections on depression as a cardiac risk factor. Psychosom Med 2005 May-Jun;67(suppl 1):S19-S25 (Pubitemid 40721027)
21. Whooley MA. Depression and cardiovascular disease: healing the broken-hearted. JAMA 2006;295(24):2874-2881 (Pubitemid 43974185)
22. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007;68 (suppl 1):20-27 (Pubitemid 46256967)
23. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007;68(suppl 4):8-13 (Pubitemid 46762118)
24. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000;61(suppl 11):37-41 (Pubitemid 30616693)
25. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62(suppl 7):22-31 (Pubitemid 32402182)
26. Taylor DM, McAskill R. Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr Scand 2000;101(6):416-432 (Pubitemid 30365564)
27. Greenberg G, Rosenheck RA. National Mental Health Program Performance Monitoring System: Fiscal Year 2006 Report. West Haven, Conn: Northeast Program Evaluation Center; 2007
28. Laing KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22
29. Green AI, Noordsy DL, Brunette MF, et al. Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat 2008;34(1):61-71 (Pubitemid 350216350)
30. Mohamed S, Rosenheck RA. Pharmacotherapy of PTSD in the US Department of Veterans Affairs: diagnostic and symptom-guided drug selection. J Clin Psychiatry 2008;69(6):959-965 (Pubitemid 351944949)
31. Bartzokis G, Lu PH, Turner J, et al. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry 2005;57(5):474-479 (Pubitemid 40311981)
32. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007;146(11):775-786 (Pubitemid 351650498)
33. Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007;176(5):627-632 (Pubitemid 46426056)
34. Chrischilles EA, Foley DJ, Wallace RB, et al. Use of medications by persons 65 and over: data from the established populations for epidemiologic studies of the elderly. J Gerontol 1992;47(5):M137-M144
35. Le Couteur DG, McLean AJ. The aging liver: drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998;34(5): 359-373 (Pubitemid 28192906)
36. Katz IR, Simpson GM, Curlik SM, et al. Pharmacologic treatment of major depression for elderly patients in residential care settings. J Clin Psychiatry 1990;51(7, suppl):41-47; discussion 48 (Pubitemid 20231060)
37. Popkin MK, Callies AL, Mackenzie TB. The outcome of antidepressant use in the medically ill. Arch Gen Psychiatry 1985;42(12):1160-1163 (Pubitemid 16191175)
38. Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996;93(11):1976-1980 (Pubitemid 26165560)
39. Pratt LA, Ford DE, Crum RM, et al. Depression, psychotropic medication, and risk of myocardial infarction: prospective data from the Baltimore ECA follow-up. Circulation 1996;94(12):3123-3129 (Pubitemid 26427477)